Wegovy Pill Sees Explosive Demand Post-Launch

The Wegovy pill, recently approved by the FDA in late December, has seen a remarkably strong start in the U.S. market since its early January launch. By January 23rd, less than three weeks post-launch, approximately 50,000 prescriptions were being filled weekly. This surge has resulted in over 170,000 individuals currently taking the medication.

Of significant note, roughly 90% of these prescriptions were paid for out-of-pocket, rather than through insurance. Most prescriptions thus far are for the lowest, starter dose, typically used by individuals beginning weight loss treatment. Novo Nordisk reported that the early uptake of the Wegovy pill has been more than double that of any previous weight loss drug launch in the United States.

This demand emerges as the GLP-1 market intensifies with various pills and injectables. The Wegovy pill offers a more affordable alternative to its injectable counterpart, with the starter dose costing $149 monthly for cash payers compared to $349 for the injectable form. A recent study in JAMA Cardiology suggested semaglutide, the ingredient in Wegovy and Ozempic, could significantly reduce heart attacks and strokes if offered at a lower price.

Experts highlight that the pill's lower price and oral form enhance accessibility. The medication aids not only in treating obesity and diabetes but also reduces the risk of heart disease, a leading cause of death. Some early demand may stem from patients switching from less expensive compounded versions of the injectable drug, following FDA directives to halt such production. Novo Nordisk expresses confidence in maintaining supply.